Atom Investors’s KalVista Pharmaceuticals KALV Stock Holding History

Atom Investors’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.95M	Sell	245,993 -30,120	-11%	-$485K	0.35%	81
2025 Q4	$4.46M	Buy	+276,113	New	+$3.66M	0.35%	89
2025 Q3	–	Sell	-16,312	Closed	-$184K	–	722
2025 Q2	$184K	Buy	+16,312	New	+$199K	0.02%	521
2024 Q3	–	Sell	-19,901	Closed	-$234K	–	535
2024 Q2	$234K	Sell	19,901 -45,104	-69%	-$526K	0.02%	406
2024 Q1	$771K	Sell	65,005 -4,839	-7%	-$64.5K	0.1%	256
2023 Q4	$856K	Buy	69,844 +4,558	+7%	+$41.5K	0.15%	204
2023 Q3	$629K	Buy	65,286 +31,727	+95%	+$324K	0.14%	195
2023 Q2	$302K	Buy	33,559 +10,975	+49%	+$101K	0.11%	188
2023 Q1	$178K	Buy	+22,584	New	+$169K	0.1%	216

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Atom Investors's KALV Position: Q1 2026 in Review

Atom Investors reduced its KalVista Pharmaceuticals (KALV) stake by 11% in Q1 2026, selling an estimated $485K and leaving 245,993 shares worth $4.95M. The position accounts for 0.35% of the portfolio, ranked #81.

Atom Investors first reported a position in KALV in Q1 2023 and has held it in 9 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Atom Investors held 245,993 shares of KalVista Pharmaceuticals worth $4.95M as of Q1 2026.
Atom Investors sold 30,120 KalVista Pharmaceuticals shares in Q1 2026, an estimated $485K.
KalVista Pharmaceuticals made up 0.35% of Atom Investors's portfolio in Q1 2026, its #81 holding.
Atom Investors first reported a position in KalVista Pharmaceuticals in Q1 2023 and has held it in 9 quarters since.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Atom Investors's 13F filing for Q1 2026, filed 15 May 2026.